Food and Drug Administration

Dermatologic & Ophthalmic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee

July 12, 2004

Briefing Information

Tazoral™ for the Treatment of Moderate to Very Severe Plaque Psoriasis Briefing Document, Allergan (PDF)

FDA Back Ground Document Regarding Oral Tazarotene for the Treatment of Moderate to Severe Psoriasis (HTM) (PDF) (Word)